Novo Nordisk's (NOVOB DC) CagriSema demonstrated superior HbA1c reduction of 1.91%-points and weight loss of 14.2% in adults with type 2 diabetes in the REIMAGINE 2 Trial
Importance
Level 1
#NOVO NORDISK A/S#NOVOB.DC#EU SESSION#US SESSION#EUROPEAN EQUITIES